BSECompany Update15h ago · 18 Nov 2026, 05:25 pm
Disclosure under Regulation 30 of SEBI (LODR)Regulations, 2015
3B BlackBio Dx Ltd · 532067
✦ AI SummaryM&A
3B BlackBio Dx Ltd, formerly known as Kilpest India Limited, has announced the acquisition of 100% shares of Bilex SRL, a Belgian company, for €274,817. The acquisition aligns with Coris BioConcept's commitment to long-term cost optimization and securing permanent infrastructure for its global diagnostic pipeline.
Analysis Scores
Earnings Impact5/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk6/10
Liquidity Impact9/10
Market Sentiment7/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
3B BlackBio Dx Ltd - 532067 - Disclosure Under Regulation 30 Of SEBI (LODR)Regulations, 2015
Attachments (1)
📄pdf
Download →
fb022817-2412-41de-9b1e-1f8adad50ca1.pdf
View document text
(Formerly – Kilpest India Limited)
Ref. No.P-66/2026-27/56
November 18th, 2026
The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001
Dear Sir / Madam,
Sub: Intimation under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-
POD2/I/3762/2026 dated January 30, 2026
This is to inform you that Coris Bioconcept SRL (hereinafter referred to as “Coris”),
subsidiary of 3B BlackBio Dx Ltd. (hereinafter referred to as “3B”) is pleased to announce
that it has entered into a definitive agreement with Bilex SRL (hereinafter referred to as
“Bilex”) to acquire 100% shares of the company.
Bilex is the owner of land and building where the Coris office and manufacturing plant
building is situated at Rue Guillaume Fouquet 11, 5032 Gembloux, Belgium. Coris shall
acquire 100% of the total paid-up share capital of Bilex on November 18th 2026 from its
shareholders Mr. Thierry Leclipteux and Mr. Joseph Bertinetti, and accordingly Bilex shall
become a subsidiary of Coris as per the conditions set out in the Share Purchase agreement
signed between the parties.
The details required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-
POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure I. A business update
on the aforesaid acquisition is enclosed as Annexure II for your perusal and information.
Further, pursuant to Regulation 30 (8) of the SEBI LODR Regulations the enclosed
disclosures and the business update are also made available on the company’s website.
This is for your information and further dissemination.
Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)
Nikhil Kuber Dubey
WholeTime Director
DIN: 00538049
Encl: As above
Regd. Office & Factory: 7-C | Industrial Area | Govindpura | Bhopal – 462023 | (M.P.) | INDIA CIN: L24211MP1972PLC001131
Ph.: 91-755-2586536, 2586537 Email: info@kilpest.com Visit us at: www.kilpest.com
(Formerly – Kilpest India Limited)
Annexure-I
Disclosure under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026
dated January 30, 2026:
S.No. Particulars Details
a) Name of the Target Entity, details in Bilex SRL,
Brief such as Size, Turnover etc.; 11, Rue Guillaume Fouquet, 5032 Isnes
(Gembloux) BELGIUM
Turnover (Rental Income) -
€227,319.00 (FY’24)
€232,267.05 (FY’25)
b) Whether the acquisition would fall The acquisition does not fall within related
within Related Party Transaction(s) party transactions. The promoter / promoter
and whether the Promoter/ group have no interest in the entity being
Promoter Group/ Group Companies acquired.
have any interest in the Entity being
acquired? If Yes, nature of interest
and details thereof and whether the
same is done at “Arm’s Length”;
c) Industry to which the Entity being None – Owned/ Occupied Manufacturing
acquired belongs; Building being acquired.
d) Objects and Impact of Acquisition 1. At present, Coris is paying rent for the
(including but not limited to, building. This acquisition transitions Coris
Disclosure of Reasons for BioConcept from a tenant to an owner-
Acquisition of Target Entity, if its occupier.
Business is outside the main line of 2. By consolidating Bilex SRL accounts into
Business of the listed entity); Coris, intercompany rental payments will
get eliminated.
3. The restructuring will generate an
immediate net annual savings of €140,000
before depreciation. Moving forward, the
only property-related expense reflected on
the consolidated financial statements will
be the direct bank interest paid on Bilex’s
long term loans apart from depreciation.
e) Brief Details of any Governmental None
or Regulatory Approvals Required
for the Acquisition;
f) Indicative Time Period for Acquisition to be completed on 18/11/ 2026
Completion of the Acquisition;
g) Consideration - Whether Cash €274,817 cash consideration for 100% shares
Consideration or Share Swap or of Bilex SRL along with payment of
any Other Form and Details of the unsecured loan of €1.32 Million to two
same; shareholders, and continuation of Bilex’s
long-term building loans of €2.11 Million at an
attractive average interest rate of 1.3 %
payable in remaining 12 years.
h) Cost of Acquisition and/or the Price Acquisition of 100% shares of Bilex SRL will
at Which the Shares are Acquired; be acquired for €274,817.
(Formerly – Kilpest India Limited)
i) Percentage of Shareholding / 100% Equity Shares will be acquired by Coris
Control Acquired and / or Number of from Bilex’s shareholders, Mr. Thierry
Shares Acquired; Leclipteux(50%) and Mr. Joseph
Bertinetti(50%).
j) Brief Background about the Entity Bilex SRL, incorporated in 2014, which is the
Acquired in terms of Products/Line owner of land and building where Coris office
of Business Acquired, Date of and manufacturing plant is situated in
Incorporation, History of last 3 years Belgium. Following the closing of this
turnover, Country in which the transaction, Bilex SRL will operate as a
Acquired Entity has presence and wholly-owned subsidiary of Coris
any other Significant Information (in BioConcept.
brief);
This transaction aligns with Coris
BioConcept's commitment to, long-term cost
optimization, and securing the permanent
infrastructure required to support its global
diagnostic pipeline.
Details of Revenue:
Year Approx. Revenue
(Rental Income)
FY2023 €203,500.00
FY2024 €227,319.00
FY2025 €232,267.05
(Formerly – Kilpest India Limited)
Annexure –II
BUSINESS UPDATE: Coris BioConcept Announces Strategic Acquisition of
100% shareholding of Bilex SRL to Optimize Costs and Secure Facility
Ownership
November 18th 2026, Gembloux, BELGIUM: Coris BioConcept SRL, a leading
innovator in rapid diagnostic kits for AMR, today announced a strategic agreement to
acquire 100% of the shares of Bilex SRL from existing shareholders Mr. Thierry
Leclipteux and Mr. Joseph Bertinetti.
Bilex SRL is the owner of land and building where Coris office and manufacturing
plant is situated. Following the closing of this transaction, Bilex SRL will operate as a
wholly-owned subsidiary of Coris BioConcept. This corporate acquisition transitions
Coris BioConcept from a tenant to an owner-occupier. By consolidating Bilex SRL
into its corporate structure, intercompany rental payments will get eliminated.
This ultra-modern building was built in 2023 is located in the Créalys® Science Park
Gembloux on a 6,443 m2 land parcel. The building has a surface area of 2,000 m²
which brings together the company’s administrative, offices and labs. It includes
state-of-the-art laboratories equipped with containment airlocks and temperature-
controlled and humidity-controlled environments. These are essential to ensure that
research conducted here is accurate and safe. This building is equipped with 256
solar panels, two 20,000-litre rainwater-collection tanks to supply the bathrooms, a
thermodynamic tank and optimized insulation. These installations reflect the
company’s desire to minimize its environmental impact while continuing to develop.
The restructuring will generate an immediate net annual savings of €140,000 before
depreciation. Moving forward, the only property-related expense reflected on the
consolidated financial statements will be the direct bank interest paid on Bilex’s
existing long term building loans apart from depreciation.
This transaction aligns with Coris BioConcept's commitment to, long-term cost
optimization, and securing the permanent infrastructure required to support its global
diagnostic pipeline.
Mr. Sébastien Goenen (CEO – Coris Bioconcept SRL) said, “We are pleased to
announce the acquisition of Bilex SRL. Transitioning from tenant to owner-occupier
secures long-term control over our core operating infrastructure and delivers
immediate, recurring savings to our cost base. Owning our Gembloux facility gives
us the stability and flexibility to invest in our manufacturing capabilities and to scale
operations in line with growing global demand for our rapid diagnostic solutions.”
Mr. Dhirendr
[Showing first 8,000 characters — download PDF for full document]